Axovant Sciences (NASDAQ:AXON) posted its earnings results on Thursday. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.27), Zacks reports.
Axovant Sciences stock traded up $0.03 during midday trading on Friday, hitting $1.25. The stock had a trading volume of 1,241,576 shares, compared to its average volume of 1,447,258. The firm has a market capitalization of $149.18 million, a price-to-earnings ratio of -0.61 and a beta of 1.21. Axovant Sciences has a 52-week low of $0.93 and a 52-week high of $6.59. The company has a current ratio of 1.97, a quick ratio of 1.97 and a debt-to-equity ratio of 1.68.
Several equities research analysts have recently commented on AXON shares. Zacks Investment Research raised shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research report on Monday, January 7th. ValuEngine lowered shares of Axovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Jefferies Financial Group raised shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Monday, December 17th. Oppenheimer reaffirmed a “hold” rating on shares of Axovant Sciences in a research report on Sunday, November 11th. Finally, BidaskClub lowered shares of Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $3.81.
In other news, major shareholder Svf Investments (Uk) Ltd bought 10,000,000 shares of Axovant Sciences stock in a transaction that occurred on Tuesday, December 18th. The stock was bought at an average cost of $1.00 per share, with a total value of $10,000,000.00. Following the acquisition, the insider now owns 99,285,714 shares of the company’s stock, valued at approximately $99,285,714. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 6.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2019/02/08/axovant-sciences-axon-announces-quarterly-earnings-results.html.
Axovant Sciences Company Profile
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
Read More: How to invest in a bear market
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.